Clinical stage company developing a unique pipeline in immuno-oncology based on GPCR-mediated immunosuppression. The lead program is an A2aR/A2bR antagonist which is in a Phase 1 study. The second program is an EP4 receptor antagonist in Phase 1. In addition, the company has an anti-CCR8 antibody program and several other preclinical stage programs. A2aR/A2bR.